CPDC joins forces with the Canadian Nuclear Isotope Council

February 19, 2019 CPDC

Hamilton, Ontario, February 19, 2019 – As Canada strives to maintain a leadership position in science and technology, the Centre for Probe Development and Commercialization (CPDC), located at McMaster University, has partnered with the Canadian Nuclear Isotope Council (CNIC) to ensure Canada remains at the forefront of medical isotope R&D and production, and to advocate for continued investment to ensure we maintain Canada’s global leadership in this field.

The CPDC was founded in 2008 as a Centre of Excellence for Commercialization and Research (CECR), specializing in radiopharmaceutical research, development and manufacturing. Since its inception, CPDC has gained global recognition as a leading radiopharmaceutical organization, developing and providing products for the diagnosis and treatment of diseases such as cancer, locally, nationally, and internationally. To date, CPDC’s products have helped diagnose and treat over 75,000 patients.

“The CNIC is creating a unified voice that is bringing attention to the work being done in the medical isotope industry in Canada,” said Joe McCann, President and CEO of CPDC. “Advancement and investment in this area has a direct benefit to Canadian cancer patients who rely daily on the supply of medical isotopes to hospitals across the country. We are incredibly pleased to join this group and we are excited to join it in bringing recognition to the incredible work being done in radioisotope and radiopharmaceutical R&D and commercialisation in Canada.”
Radiopharmaceuticals are a special class of drugs used for the diagnosis and treatment of diseases, such as cancer, Dr. McCann added. Diagnostic drugs target disease and deliver isotopes that emit photons to ‘light up’ the disease to help doctors diagnose and stage patients. Radiotherapeutics target the disease and deliver precise, cell-killing radiation that spares normal healthy tissue, and clears rapidly from blood and tissues.

“The CPDC works with partners, such as the Ontario Institute for Cancer Research and Prostate Cancer Canada, to develop diagnostic and therapeutic radiopharmaceuticals for clinical trials, keeping Canada at the forefront of radiopharmaceutical research and development. “Canada has long been a historical leader in isotope production and has fostered an innovative industry that has saved millions of lives around the world.”

Isotopes are the foundation to advance research for improved drug discovery and development, said James Scongack, Chair of the CNIC.
“Isotopes are our pathway to personalized medicine – enabling health-care professionals to improve lives through targeted imaging and therapy, thereby providing medical diagnosis and treatment specific to an individual,” Scongack said. “This field of targeted radiotherapeutics could be transformative for both the Canadian and global health care sectors, which is why we are delighted to have CPDC become a member of the CNIC and partner with us on our advocacy initiatives.”

The world has come to depend on a commitment that every Canadian government has supported for over 50 years, Scongack added.
“Retaining a secure supply of isotopes and infrastructure in Canada will allow us to maintain a leading position in the development of new nuclear medicine technologies, benefitting both Canadians and the advancement of science. This also fits with the federal government’s announced strategy of building up our science and technology capabilities.”

About the Canadian Nuclear Isotope Council
The CNIC is a coalition of science, health care and nuclear sector organizations to ensure Canada remains a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international level that will save countless lives and support health care innovation for decades to come. To learn more about the CNIC visit www.CanadianIsotopes.ca.

About the Centre for Probe Development and Commercialization
Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE) and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. To learn more about CPDC visit www.imagingprobes.ca.

Canadian Nuclear Isotope Council
Andrew Thiele, 226 930-1869

Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212

More news from CPDC

AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego

HAMILTON ON, Aug. 24, 2022 – AtomVie Global Radiopharma Inc. (“AtomVie”) today announced the successful closing of its Series A financing with Avego Management, LLC (“Avego”), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Organization) for the development, manufacturing, and global distribution of radiopharmaceuticals and has received a financing commitment of at

CPDC executes its first commercial sublicensing agreement with Lawson Health Research Institute for PSMA-1007, expanding access to the prostate cancer diagnostic agent in Ontario

HAMILTON, ON, June 28, 2022 /CNW/ – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH (Radeberg, Germany) and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada. Concurrently, CPDC is also pleased to

Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America.

For more information contact us at: